Senior Correspondent, London
Ben's Feed
Sep 2, 2014
Sep 1, 2014

Pricing is key for new heart drugs challenging cheap generics

BARCELONA (Reuters) – Doctors looking at highly encouraging clinical trial results for new heart drugs at the world’s largest cardiology meeting this week are missing one piece of data that will be critical to their success – the price.

While new treatments on show in Barcelona are certainly moving cardiovascular medicine forward after a series of setbacks in recent years, cardiologists say that cost will be key in determining how widely they are used.

Sep 1, 2014

Analysis – Pricing is key for new heart drugs challenging cheap generics

BARCELONA (Reuters) – Doctors looking at highly encouraging clinical trial results for new heart drugs at the world’s largest cardiology meeting this week are missing one piece of data that will be critical to their success – the price.

While new treatments on show in Barcelona are certainly moving cardiovascular medicine forward after a series of setbacks in recent years, cardiologists say that cost will be key in determining how widely they are used.

Sep 1, 2014
Sep 1, 2014
Sep 1, 2014

‘Most exciting ever’ Novartis drug points to huge sales

BARCELONA (Reuters) – Sales forecasts for Novartis’s new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease.

Shares in the Swiss drugmaker jumped over 3 percent to a record high on Monday as data for LCZ696 released at the weekend beat expectations, showing the medicine slashed deaths and hospitalizations, worked across all groups of patients, and had no serious side effects.

Sep 1, 2014

Cyberonics device improves heart function after Boston flop

BARCELONA (Reuters) – A nerve stimulation device from Cyberonics improved cardiac function in heart failure patients in a small clinical trial, in contrast to an unsuccessful study backed by Boston Scientific.

However, the Cyberonics trial reported on Monday did not contain a control arm – unlike the one using the Boston device in which some patients received sham treatment – and experts said further research was now needed.

Sep 1, 2014

Astra heart pill safe to use in ambulance but no extra benefit

BARCELONA, Sept 1 (Reuters) – AstraZeneca’s
blood-thinning drug Brilinta is safe to use in the ambulance
when heart attack patients are being rushed to hospital but
giving it early in this way does not provide any extra benefit.

That is the conclusion of a clinical study presented on
Monday at the European Society of Cardiology congress, which
suggests the drug is a flexible treatment option for doctors.

Aug 31, 2014
Aug 31, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben